ResearchPod Summary
Young women diagnosed with breast cancer face the challenge of chemotherapy-induced gonadotoxicity, which can lead to premature ovarian insufficiency (POI), infertility, and the onset of early menopausal symptoms. While international guidelines emphasize counseling on these risks, there has been ongoing controversy regarding the efficacy and safety of using gonadotropin-releasing hormone agonists (GnRHa) to temporarily suppress ovarian function during systemic treatment. This study provides a definitive look at this strategy using individual patient-level data.
The researchers performed a systematic review and meta-analysis of five randomized trials, including 873 premenopausal women with early breast cancer. Participants were randomized to receive either chemotherapy alone or chemotherapy in combination with GnRHa. The study analyzed the incidence of POI as the primary endpoint, along with post-treatment pregnancy rates and safety outcomes, specifically disease-free survival (DFS) and overall survival (OS). The researchers employed a random effects model to account for the clustering effect of the different studies.
The analysis demonstrated a clear protective effect of GnRHa. Patients who received GnRHa during chemotherapy had an significantly lower risk of developing POI (14.1%) compared to the control group (30.9%). Furthermore, the GnRHa group showed a higher rate of post-treatment pregnancies (10.3%) compared to the control group (5.5%). Importantly, the study found no evidence of a negative impact on cancer prognosis; both DFS and OS were statistically similar between the treatment and control groups, regardless of the patient's estrogen receptor status. While GnRHa usage increased mild-to-moderate side effects such as hot flashes, it provided a viable medical pathway for preserving ovarian health without compromising oncological outcomes.
The findings offer strong evidence that GnRHa should be considered an available option for premenopausal breast cancer patients undergoing (neo)adjuvant chemotherapy. It serves as a meaningful intervention to minimize the long-term quality-of-life impacts of POI. This approach is particularly relevant for patients who may not have access to standard fertility preservation techniques like oocyte or embryo cryopreservation, or as an additional strategy to augment these established methods.
AI-generated third-party summary by ResearchPod. Not official content or an endorsement by the paper authors or affiliated organizations.